Edible plants are increasingly recognised as promising nutraceutical options for various diseases,including cancer.We were the first to discover that Crithmum maritimum L.,an edible wild plant,inhibits the growth of h...Edible plants are increasingly recognised as promising nutraceutical options for various diseases,including cancer.We were the first to discover that Crithmum maritimum L.,an edible wild plant,inhibits the growth of hepatocellular carcinoma cells by targeting multiple metabolic pathways,such as lactic acid fermentation and biosynthetic pathways characteristic of tumour cells.In this study,we investigated the effects of ethyl acetate extract of Crithmum maritimum on the growth inhibition of four different cancer types:colon,pancreatic,breast,and glioblastoma.Our results demonstrate that Crithmum maritimum significantly suppresses the in vitro growth of all four tumour types by inducing a metabolic shift from fermentation to respiration,which correlates with improved metabolic enzyme markers.In particular,we demonstrated that Crithmum maritimum reduces lactic acid fermentation by decreasing the gene expression ratio of two lactate dehydrogenase isoforms(LDHA/LDHB),thereby lowering the production of L-lactate.We also showed that Crithmum maritimum promotes the restoration of a more normal cellular redox potential by enhancing NAD^(+)production at the expense of NADH.Furthermore,we observed Crithmum maritimum-mediated recovery of mitochondrial function through stimulation of cellular respiration and modulation of the gene expression of cytochrome c oxidase subunits(COXs),specifically COX I,COX IV-1,and COX IV-2.Notably,we described the anti-inflammatory and anti-cholesterolaemic effects of Crithmum maritimum.Taken together,our findings underscore the potential of Crithmum maritimum L.as a valuable nutraceutical supplement for conventional pharmacological therapies for various types of tumours.展开更多
基金supported by the“Tecnonidi”project,promoted by Regione Pugliafunded by Olivhealth Srl,Italy.
文摘Edible plants are increasingly recognised as promising nutraceutical options for various diseases,including cancer.We were the first to discover that Crithmum maritimum L.,an edible wild plant,inhibits the growth of hepatocellular carcinoma cells by targeting multiple metabolic pathways,such as lactic acid fermentation and biosynthetic pathways characteristic of tumour cells.In this study,we investigated the effects of ethyl acetate extract of Crithmum maritimum on the growth inhibition of four different cancer types:colon,pancreatic,breast,and glioblastoma.Our results demonstrate that Crithmum maritimum significantly suppresses the in vitro growth of all four tumour types by inducing a metabolic shift from fermentation to respiration,which correlates with improved metabolic enzyme markers.In particular,we demonstrated that Crithmum maritimum reduces lactic acid fermentation by decreasing the gene expression ratio of two lactate dehydrogenase isoforms(LDHA/LDHB),thereby lowering the production of L-lactate.We also showed that Crithmum maritimum promotes the restoration of a more normal cellular redox potential by enhancing NAD^(+)production at the expense of NADH.Furthermore,we observed Crithmum maritimum-mediated recovery of mitochondrial function through stimulation of cellular respiration and modulation of the gene expression of cytochrome c oxidase subunits(COXs),specifically COX I,COX IV-1,and COX IV-2.Notably,we described the anti-inflammatory and anti-cholesterolaemic effects of Crithmum maritimum.Taken together,our findings underscore the potential of Crithmum maritimum L.as a valuable nutraceutical supplement for conventional pharmacological therapies for various types of tumours.
